Determination of Regulatory Review Period for Purposes of Patent Extension; ENJAYMO

Summary

The US Food and Drug Administration (FDA) has determined the regulatory review period for patent extension for human biological products, following a submission to the US Patent and Trademark Office (USPTO), Department of Commerce. The FDA is publishing this notice as required by law.